the investment conditions, and societal attitudes towards new technologies.
On several measures, other developed countries spend proportionately as much as the US on research and development. The table presents the spending on research and development as a percentage of gross domestic product for eight developed countries. 14 The US is about at the median. Prices in the countries with better ratios than the US were 31-36% less than those in the US. 15 Pharmaceutical companies commit as large a percentage of sales to research and development in Europe as in the US, about 19% on average over the past seven years. 9 13 This little reported fact contradicts the widely circulated claims that European countries deliberately ignore research and development costs in calculating prices. 1
Europe no less innovative than the US
Contrary to claims of American dominance, pharmaceutical research and development in the US has not produced more than its proportionate share of new molecular entities. The US accounts for just under 48% of world sales and spent 49% of the global total on research and development to discover 45% of the new molecular entities that were launched on the world market in 2003, less than its proportionate share. European countries account for 28% of world sales, 36% of total research and development spending, and 32% of new molecular entities, more than its proportionate share. 13
Limited investment in breakthrough research
Pharmaceutical research and development is traditionally divided into three categories:
x Basic-work to discover new mechanisms and molecules for treating a disorder x Applied-work that develops a discovery into a specific practical application, including research on manufacturing processes and preclinical or clinical studies x Other-work that includes drug regulation submissions, bioavailability studies, and post-marketing trials.
Although all types of research are valuable, it is basic research that leads to important therapeutic breakthroughs. Only a fraction of overall industry expenditure is on basic research, and it does not require the high prices currently seen in the US to support it.
The Pharmaceutical Research and Manufacturers of America reports that companies invest on average about 18-19% of domestic sales into research. 9 This figure is considerably higher than that produced by the US National Science Foundation. 16 Its 1999 data show that drug companies invest 12.4% of gross domestic sales on research and development (10.5% in-house and 1.9% contracted out), but only 18% of the amount spent in-house went on basic research. Assuming that 18% of contracted out research is also spent on basic research (the actual figure is not reported) then only 2.2% (18%×12.4%) of revenue goes to basic research. The after tax cost of $1 of research and development expenditures in the US seems to be $0.53 to $0.61, owing to tax incentives to do research. 17 Thus US pharmaceutical companies devote a net of only about 1.3 cents (2.4%×(0.53+0.61)/2) of every dollar from sales to innovation.
Only 10-15% of newly approved drugs provide important benefits over existing drugs. 18 19 From a drug company's point of view, investing principally in research to produce new variations of existing drugs makes sense. Government protections from normal price competition do not distinguish between the lower risk, less costly derivative kind of research and high risk basic research needed to discover new molecules.
Misusing economic theory
The industry's principal claims, as well as being contradicted, are based on false premises. Firstly, counting which country discovers the most new molecular entities is irrelevant in a global market. Companies know that where a good drug is discovered does not matter, and often a discovery comes from research in several countries. Whether domestic revenues recover a given country's research and development costs is also irrelevant. If this were not the case the industry would have shut down operations in Switzerland long ago because of its small market size.
If revenues are inadequate, it would make more sense to conclude they do not cover all marketing costs rather than research costs. Research is central to the industry, and costs associated with it should be deducted first. Pharmaceutical companies report that they invest around three times more in the combination of marketing, advertising, and administration than in research, leaving ample room to cut costs. 20 Secondly, every student in introductory economics learns that fixed costs like research do not determine prices. 21 The market sets prices, implying they are open to free trading like stock prices. Patents, and especially patent clusters, turn the market into a monopoly, and only a monopoly can claim that fixed costs determine prices because it can make that a self fulfilling prophecy. The claim by companies that they have to set prices at 50-100 times production costs to recover research and development costs has never been substantiated, because they have never opened their books to independent public inspection to prove it. What we do know is that all research and development costs are fully recovered each year from domestic sales in the UK and Canada at prices that are far lower than those in the US.
Thirdly, free rider is both a vivid public image of someone jumping on for a free ride and a highly misleading economic term. Technically it refers to a method for allocating fixed costs in proportion to the prices that different groups pay. For example, if Group A (call it Europe) pays $1 per pill and Group B (call it Ratio of pharmaceutical spending on research and development to gross domestic product and ratio of drug prices to US prices, 2000 
